{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:34:48Z","timestamp":1773866088198,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The primary aim of this study was to evaluate the effect of oral dydrogesterone on the recurrent uterine contraction in preterm labor. The secondary aims were to evaluate latency period, gestational age at delivery, pregnancy outcomes, neonatal outcomes, compliance and side effects. A randomized, double blinded, placebo controlled trial was conducted. Forty-eight pregnant women at 24\u201334 weeks gestation with preterm labor were either randomized to study group receiving tocolytic treatment combined with oral dydrogesterone (20\u2009mg daily) or to placebo group receiving tocolytic treatment combined with oral placebo. Recurrent rates of uterine contraction were comparable between groups (87.5% vs 91.7%, p\u2009=\u20090.64). Latency periods were not different between dydrogesterone and placebo group (32.7\u2009\u00b1\u200920.2 days vs 38.2\u2009\u00b1\u200924.2 days, p\u2009=\u20090.39). There were also no differences in gestational age at delivery, pregnancy outcomes, neonatal outcomes, compliance and side effects. Adjuvant treatment with oral dydrogesterone 20\u2009mg\/day could not decrease the rates of recurrent uterine contraction and prolong latency period in preterm labor management when compared to placebo.<\/jats:p>","DOI":"10.1038\/srep20638","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T10:40:37Z","timestamp":1455014437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor"],"prefix":"10.1038","volume":"6","author":[{"given":"Wilasinee","family":"Areeruk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vorapong","family":"Phupong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,9]]},"reference":[{"key":"BFsrep20638_CR1","doi-asserted-by":"crossref","unstructured":"ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol. 119, 1308\u20131317 (2012).","DOI":"10.1097\/AOG.0b013e31825af2f0"},{"key":"BFsrep20638_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2471\/BLT.08.062554","volume":"88","author":"S Beck","year":"2010","unstructured":"Beck, S. et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ, 88, 31\u201338 (2010).","journal-title":"Bull World Health Organ"},{"key":"BFsrep20638_CR3","doi-asserted-by":"crossref","unstructured":"Theplib, A. & Phupong, V. Success rate of terbutaline in inhibiting preterm labor for 48 h. J Matern Fetal Neonatal Med 2015 (In press).","DOI":"10.3109\/14767058.2015.1021671"},{"key":"BFsrep20638_CR4","doi-asserted-by":"crossref","unstructured":"ACOG Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 120, 964\u2013973 (2012).","DOI":"10.1097\/AOG.0b013e3182723b1b"},{"key":"BFsrep20638_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1055\/s-0029-1215432","volume":"26","author":"ZT Henderson","year":"2009","unstructured":"Henderson, Z. T., Power, M. L., Berghella, V., Lackritz, E. M. & Schulkin, J. Attitudes and practices regarding use of progesterone to prevent preterm births. Am J Perinatol. 26, 529\u2013536 (2009).","journal-title":"Am J Perinatol"},{"key":"BFsrep20638_CR6","first-page":"45","volume":"4","author":"SH Sharami","year":"2010","unstructured":"Sharami, S. H., Zahiri, Z., Shakiba, M. & Milani, F. Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo-controlled double-blind trial. Int J Fertil Steril. 4, 45\u201350 (2010).","journal-title":"Int J Fertil Steril"},{"key":"BFsrep20638_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3109\/01443615.2013.820266","volume":"33","author":"A Areia","year":"2013","unstructured":"Areia, A., Fonseca, E. & Moura, P. Progesterone use after successful treatment of threatened pre-term delivery. J Obstet Gynaecol. 33, 678\u2013681 (2013).","journal-title":"J Obstet Gynaecol"},{"key":"BFsrep20638_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1479-828X.2007.00803.x","volume":"48","author":"S Borna","year":"2008","unstructured":"Borna, S. & Sahabi, N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 48, 58\u201363 (2008).","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"BFsrep20638_CR9","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3109\/14767058.2011.629014","volume":"25","author":"DA Bomba-Opon","year":"2012","unstructured":"Bomba-Opon, D. A. et al. Vaginal progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonatal Med. 25, 1156\u20131159 (2012).","journal-title":"J Matern Fetal Neonatal Med"},{"key":"BFsrep20638_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000328719","volume":"72","author":"I Arikan","year":"2011","unstructured":"Arikan, I., Barut, A., Harma, M. & Harma, I. M. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 72, 269\u2013273 (2011).","journal-title":"Gynecol Obstet Invest"},{"key":"BFsrep20638_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0028-2243(91)90118-5","volume":"40","author":"G Noblot","year":"1991","unstructured":"Noblot, G., Audra, P., Dargent, D., Faguer, B. & Mellier, G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 40, 203\u2013209 (1991).","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BFsrep20638_CR12","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","volume":"46","author":"AE Schindler","year":"2003","unstructured":"Schindler, A. E. et al. Classification and pharmacology of progestins. Maturitas. 46 Suppl 1, S7\u2013S16 (2003).","journal-title":"Maturitas"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep20638","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:17:51Z","timestamp":1672838271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep20638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,9]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,26]]}},"alternative-id":["BFsrep20638"],"URL":"https:\/\/doi.org\/10.1038\/srep20638","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,9]]},"assertion":[{"value":"27 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20638"}}